While European harmonisation continues apace, national differences continue to affect how best to construct a patent claim, say Magdalena Tagowska and Agnieszka Zebrowska-Kucharzyk.
While European harmonisation continues apace, national differences continue to affect how best to construct a patent claim, say Magdalena Tagowska and Agnieszka Zebrowska-Kucharzyk.
According to Article 63, point 2 of the Polish Industrial Property Law (IPL), patent claims should be interpreted based on the specification and drawings. This requirement is not unique to the Polish IPL; a similar regulation can be found in European patent legislation.
However, even though the European legislation predates Poland’s IPL, the actual interpretation of claims differs from one country to another. The question of how to construct patent claims in order to obtain the optimal scope of protection remains crucial.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
biotechnology, pharmaceuticals, harmonisation, CJEU, EPO
